Liseth M Parra, PhD

Global oncology drug discovery. All opinions are my own.

[Liseth M Parra, PhD @lisethmparra]

@maggiejuang1 @KUWTKWorld Many people in the Midwest don’t know there is a world outside of the Midwest.

[Nature Reviews Drug Discovery @NatRevDrugDisc]

The maligant melonama market https://t.co/w9ehoMHW28

A new analysis of the late-stage pipeline of novel therapies for malignant melanoma, such as LAG3 inhibitors, mRNA vaccines and cell therapies, and their potential market impact by @RWebsterDRG and colleagues

[Nature Reviews Drug Discovery @NatRevDrugDisc]

For readers interested in drugs targeting the LAG3 immune checkpoint in melanoma and beyond, here's a recent news article ICYMI https://t.co/ZqBZsF80HS

[Liseth M Parra, PhD @lisethmparra]

I'm attending REUTERS NEXT - uniting global leaders and forward thinkers to reimagine solutions to the challenges the new year brings. Registration is free for a limited time only, register now https://t.co/pb2TjP7aBs

[Liseth M Parra, PhD @lisethmparra]

$GSK wins first-in-class #BCMA-targeting antibody-drug conjugate #BLENREP (belantamab mafodotin) for heavily treated r/r multiple myeloma patients -DREAMM-2 https://t.co/UU10rGtxNZ

[Liseth M Parra, PhD @lisethmparra]

Welcome to Mass: German biotech #MorphoSys set to expand its presence in Boston after gaining its first approval with #monjuvi (tafasitamab-cxix) as a #DLBCL Tx $MOR https://t.co/7qx1qMRar9 via @BosBizJournal

[Liseth M Parra, PhD @lisethmparra]

CARTs expand to refractory mantel cell lymphoma: Gilead and Kite's #Tecartus (brexucabtagene autoleucel) receives #FDA accelerated approval as first cell-based gene Tx for #MCL $GILD https://t.co/sYS9EgyEav

[Liseth M Parra, PhD @lisethmparra]

#FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma based on results from the ZUMA-2 trial #MCL $GILD https://t.co/mwB4O7DWpY

[Liseth M Parra, PhD @lisethmparra]

Immunotherapy milestone in the maintenance setting: #FDA Approves the PD-L1 inhibitor #Bavencio (avelumab) as frontline maintenance in metastatic bladder cancer (urothelial carcinoma) $PFE $MRK https://t.co/ldnfeUinHS via @onclive

[Liseth M Parra, PhD @lisethmparra]

In the CoVID-19 era: #FDA Approves Breast Cancer Treatment #Phesgo (Herceptin+Perjeta) That Can Be Administered At Home By Health Care Professional $RHHBY https://t.co/eUVlZ0EmZo

[Liseth M Parra, PhD @lisethmparra]

Another milestone for precision medicine: #FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer $MRK https://t.co/hgqUJOkbOh

[Liseth M Parra, PhD @lisethmparra]

Read my blog: #Keytruda Poised to Change the Front-Line Treatment of MSI-H/dMMR mCRC | DRG Blog | #DRG https://t.co/mvRPdPbIjK

[Liseth M Parra, PhD @lisethmparra]

FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional https://t.co/eUVlZ0mM7Q

[Liseth M Parra, PhD @lisethmparra]

Karyopharm Announces #FDA Approval of #XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) $KPTI https://t.co/nHN9V85BUo

[Liseth M Parra, PhD @lisethmparra]

More on precision medicine in cancer: the #FDA has now granted accelerated approval to #Tazverik (tazemetostat) for the treatment of advanced follicular lymphoma patients harboring EZH2 mutations $EPZM https://t.co/OqFs0SogDH

[Liseth M Parra, PhD @lisethmparra]

the #FDA has approved Merck & Co.'s #KEYTRUDA, as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors, that have progressed following prior treatment $MRK https://t.co/k9tAGh6b6k

[Liseth M Parra, PhD @lisethmparra]

Check out my new blog: Keytruda Poised to Change the Front-Line Treatment of MSI-H/dMMR mCRC | DRG Blog | DRG https://t.co/mvRPdPbIjK

[Liseth M Parra, PhD @lisethmparra]

FDA grants accelerated approval to #ZEPZELCA (lurbinectedin) for metastatic small cell lung cancer after disease progression $PHMMF https://t.co/iAN5EfwqKN

[Liseth M Parra, PhD @lisethmparra]

AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history $AZN $GILD https://t.co/r1yzXsdnMX via @PharmaTechFocus

[Clarivate @Clarivate]

We believe a spark of human ingenuity can change the world. @Clarivate operates at the ❤️ of the lifecycle of innovation, giving our customers the insights they need to turn a bold idea into a big innovation.

This is our story: https://t.co/O5LslccH5Y

#IdeatoInnovation